Long-term efficacy of bezafibrate in reduction of small, dense low- density lipoprotein by hypotriglyceridemic action

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 3, 2000, Pages 127-136

  Hirano, Tsutomu ^a   Kazumi, Tsutomu ^b   Yoshino, Gen ^c  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hyogo Rehabilitation Center Hospital   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bezafibrate; Dense LDL; HDL cholesterol; Small; Triglyceride

Indexed keywords

BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MALE; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034041717     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80010-7     Document Type: Article

References (19)

1. 1. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: Guidance from Framingham: A statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation. 1998;97:1876-1887.
2. 2. Lamarche B, Despres JP, Moorjani S, et al. Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Quebec Cardiovascular Study. Atherosclerosis. 1996;119:235-245.
3. 3. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
4. 4. McNamara JR, Jenner JL, Li Z, et al. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb. 1992;12:1284-1290.
5. 5. Coresh J, Kwiterovich PO, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34:1687-1697.
6. 6. Katzel LI, Krauss RM, Goldberg AP. Relations of plasma TG and HDL-C concentrations to body composition and plasma insulin levels are altered in men with small LDL particles. Arterioscler Thromb. 1994;14:1121-1128.
7. 7. Yoshida H, Ishikawa T, Ayaori M, et al. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: A randomized, double-blind, placebo-controlled study. Atherosclerosis. 1998;139:179-187.
8. 8. Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16:763-772.
9. 9. Toyota Y, Yamamura T, Miyake Y, Yamamoto A. Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis. 1999;147:77-86.
10. 10. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656.
11. 11. Freidewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. 12. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 1986;128:417-431.
13. 13. Hirano T, Naito H, Kurokawa M, et al. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis. 1996;123:57-72.
14. 14. Hirano T, Oi K, Sakai S, et al. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: A possible role of postprandial lipemia. Atherosclerosis. 1998;141:77-85.
15. 15. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10:245-257.
16. 16. Deckelbaum RJ, Grannot E, Oschry Y, et al. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis. 1984;4:225-231.
17. 17. Griffin BA, Freeman DJ, Tait GW, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106:241-253.
18. 18. Karpe F, Tornvall P, Olivecrona T, et al. Composition of human low density lipoprotein: Effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis. 1993;98:33-49.
19. 19. Weintraub MS, Charach G, Grosskopf I. Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis. 1998;141:S71-S75.